Kymera Therapeutics (NASDAQ:KYMR - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Truist Financial in a note issued to investors on Friday, Benzinga reports. They currently have a $53.00 price objective on the stock, down from their prior price objective of $54.00. Truist Financial's price target suggests a potential upside of 15.07% from the company's current price.
KYMR has been the topic of a number of other research reports. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a report on Monday, August 26th. Morgan Stanley upped their target price on Kymera Therapeutics from $34.00 to $45.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 14th. Leerink Partnrs raised Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Leerink Partners reissued an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, Wells Fargo & Company increased their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a research report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.92.
Check Out Our Latest Stock Analysis on Kymera Therapeutics
Shares of NASDAQ:KYMR traded down $0.11 during trading on Friday, reaching $46.06. The stock had a trading volume of 81,952 shares, compared to its average volume of 595,744. The business has a fifty day moving average price of $47.06 and a 200-day moving average price of $40.57. The stock has a market cap of $2.84 billion, a PE ratio of -19.19 and a beta of 2.21. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $53.27.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same quarter in the previous year, the business earned ($0.90) EPS. The company's quarterly revenue was down 20.9% compared to the same quarter last year. Sell-side analysts expect that Kymera Therapeutics will post -2.85 earnings per share for the current year.
In related news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KYMR. Price T Rowe Associates Inc. MD lifted its stake in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company's stock worth $254,548,000 after purchasing an additional 996,300 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company's stock worth $191,635,000 after acquiring an additional 769,486 shares during the last quarter. Artal Group S.A. increased its position in shares of Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company's stock worth $121,691,000 after acquiring an additional 496,400 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Kymera Therapeutics during the first quarter worth about $17,122,000. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Kymera Therapeutics during the second quarter worth about $6,669,000.
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.